Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial infarction (MI), stroke, or all-cause mortality, a new analysis of real-world data suggests.
Safety findings were similar, except for the fact that genital infections were more common with SGLT-2 inhibitors.
